Adacel vaccine professional information

The threat of pertussis
may not be obvious to them.
Thankfully, it’s obvious to you.
Adacel vaccine is indicated for active booster immunization for
the prevention of tetanus, diphtheria, and pertussis as a single
dose in persons 11 through 64 years of age.
Page 1 of 6
Family members are the primary source of pertussis in infants1
Studies show that when the source can be
identified, family members are the source in
up to 83% of cases transmitted to infants1
s of infant pertu
rce
ssi
u
s
So
Family
Mother
Father
International multicenter study of 91 families
1
• Source cases were identified for 44 infants and described
by relationship to the infant, age, and household status1
Siblings
O
t
he
Infants under 6 months of age are most
vulnerable to complications from pertussis2
Friends, Cousins, and
Part-time Caretakers
r
Aunts and Uncles
Grandparents
Despite CDCa recommendations, only 8% of adults reported
receiving Tdapb vaccine from 2005 through 2010.3,4
Pediatricians play a vital role in helping to protect
families against pertussis by:
• Informing parents about the threat pertussis poses to families and the importance
of immunization with Tdap
• Continuing to immunize eligible adolescents ≥11 years of age with Adacel vaccine
a CDC = Centers for Disease Control and Prevention.
b Tdap = Tetanus, diphtheria, and acellular pertussis.
Please click here for Important
Safety Information.
Page 2 of 6
Adacel vaccine—the Tdap vaccine that shares your commitment
Adacel vaccine is dedicated to informing the public about the threat of pertussis
to make your conversations with parents short and effective
• Adacel vaccine encourages parents to take an active role in pertussis prevention
through a variety of channels, including:
– Direct-to-patient
communications
– Televised public service
announcements
–E
ducational Web sites
for parents
With G.I.F.T., choosing Adacel vaccine helps
extend pertussis protection
Adacel vaccine is committed to helping protect more families who
can’t afford vaccination against pertussis.
For every 100 doses of Adacel vaccine sold, Sanofi Pasteur donates
1 dose to AmeriCares® for the immunization of uninsured mothers
and family members across the United States. AmeriCares identifies
public and community health facilities to receive the doses.
• The G.I.F.T. program began in September 2010 and will
continue through May 31, 2013, adding to the 150,000 doses
already donated
Please click here for G.I.F.T. program Terms and Conditions.
For more information about Adacel vaccine and
pertussis, please visit www.AdacelVaccine.com.
Please click here for Important Safety Information.
One shot. Big impact.
Page 3 of 6
Adacel vaccine provides extensive real-world, clinical
experience for adult and adolescent pertussis vaccination
in the United States
Over 67 million doses supplied in the
United States since licensure in 2005.5
Adacel vaccine has demonstrated immunogenicity in clinical trials6
Adacel vaccine has a safety profile similar to Tdc vaccine6
• Serious adverse events were uncommon and comparable in frequency to Td vaccine6
• Injection site pain was common and more frequent in adolescents receiving Tdap
compared with Td vaccine6
Please click here for Important Safety Information.
c Td = Tetanus and diphtheria.
Page 4 of 6
Easy ways to implement Tdap in your practice
Here are a few simple suggestions for how to help ensure families and
vulnerable infants in your practice are protected against pertussis
Screen parents for Tdap immunization status during routine newborn or
1-month visits and use chart stickers to note the status in the baby’s file
Have the nurse ask parents about Tdap immunization status during
appointment check-in or when checking infant’s weight and height
Place reminders near scales or the check-in desk that encourage adult contacts
to seek Tdap immunization from their primary-care providers or pharmacists
Include the Vaccine Information Sheet for Tdap along with other educational
materials in newborn visit packets
Display Tdap information brochures in waiting and examination rooms, and
include Tdap information on your practice’s Web site
Ensure members of your staff are immunized with Tdap
Use WellConnect® to contact all parents of children under 12 months of age
Thank you for your commitment to help protect
families against pertussis
Speak to your Sanofi Pasteur sales representative about your Tdap vaccine
needs. You may also order Adacel vaccine at VaccineShoppe.com® or call
1-800-VACCINE (1-800-822-2463).
For more information about Adacel vaccine and
pertussis, please visit www.AdacelVaccine.com.
Please click here for Important Safety Information.
One shot. Big impact.
Page 5 of 6
IMPORTANT SAFETY INFORMATION
INDICATION
Adacel vaccine is indicated for active booster immunization for the prevention of tetanus,
diphtheria, and pertussis as a single dose in persons 11 through 64 years of age. SAFETY INFORMATION
The most common local and systemic adverse reactions to Adacel vaccine include injection
site pain, erythema, and swelling; headache, body ache, tiredness, and fever. Other adverse
reactions may occur. A severe allergic reaction after a previous dose of Adacel vaccine
or any other tetanus toxoid, diphtheria toxoid, or pertussis-containing vaccine, or to any
component, or encephalopathy within 7 days of a previous dose of a pertussis-containing
vaccine, is a contraindication.
The decision to give Adacel vaccine should be based on the potential benefits and risks;
especially if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine
containing tetanus toxoid; if progressive or unstable neurologic disorders exist; or if adverse
events have occurred in temporal relation to receipt of pertussis-containing vaccine. Persons
who experienced Arthus-type hypersensitivity reactions following a prior dose of tetanus
toxoid-containing vaccine should not receive Adacel vaccine less than 10 years since the
last dose of tetanus toxoid-containing vaccine. The tip caps of the prefilled syringes may
contain natural rubber latex, which may cause allergic reactions in latex-sensitive individuals.
Vaccination with Adacel vaccine may not protect all individuals.
Before administering Adacel vaccine, please click here for accompanying full Prescribing Information.
CPT®d Code: 90715
d CPT = Current Procedural Terminology is a registered trademark of the American Medical Association.
Adacel vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.
References: 1. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26:293-299. 2. Centers for Disease Control and
Prevention (CDC). Pertussis. In: Atkinson W, Wolfe C, Hamborsky J, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed. Washington, DC: Public Health Foundation;
2011:215-232. 3. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the
Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among
health-care personnel. MMWR. 2006;55(RR-17):1-37. 4. CDC. Adult vaccination coverage—United States, 2010. MMWR. 2012;61(4):66-72. 5. Sanofi Pasteur Inc. Data on file (Adacel vaccine direct
doses distributed), October 11, 2011. MKT24538. 6. Adacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2012.
Page 6 of 6
Sanofi Pasteur. Discovery Drive. Swiftwater, Pennsylvania 18370. www.sanofipasteur.us
MKT25096
© 2012 Sanofi Pasteur Inc.
11/12
Printed in USA